Viking Therapeutics, Inc. (VKTX) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.77: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum.
Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for obesity in Phase 3 VANQUISH trials (SC) and Phase 3 initiation planned Q3 2026 (oral), plus VK2809 for NASH/MASH. No products approved; relies on Ligand-licensed... Read more
Sell if holding. Engine safety override at $28.77: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Score 4.2/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 47d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Viking Therapeutics, Inc.
Latest news
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga Jun 5, 2026 neutral
- NEWS Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89 — benzinga May 28, 2026 positive
- NEWS Viking Therapeutics Presents Additional Data From Phase 2 VENTURE-Oral Dosing Trial Evaluating Oral Tablet Formulation O — benzinga May 12, 2026 positive
- NEWS Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port — benzinga May 4, 2026 neutral
- NEWS Cantor Fitzgerald Maintains Overweight on Viking Therapeutics, Lowers Price Target to $100 — benzinga Apr 30, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.77: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Prior stop was $26.74. Score 4.2/10, moderate confidence.
Take-profit target: $32.50 (+13.0% upside). Prior stop was $26.74. Stop-loss: $26.74.
DATA_ISSUE: analyst_target_implausible (raw $92.58 vs price $28.75 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (1.5 < 4.0).
Viking Therapeutics, Inc. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 5.0/10. Verdict: Sell.
26 analysts cover VKTX with a consensus score of 4.2/5. Average price target: $93.
What does Viking Therapeutics, Inc. do?Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for...
Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for obesity in Phase 3 VANQUISH trials (SC) and Phase 3 initiation planned Q3 2026 (oral), plus VK2809 for NASH/MASH. No products approved; relies on Ligand-licensed technology and CordenPharma for VK2735 API and fill/finish manufacturing under multi-year agreements.